PBYIPuma Biotechnology, Inc.
$11.03+111% 1Y
$11.03
$4.7352 weeks$11.28
Price
+111%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, nothing alarming, price roughly fair, growth fading, the market undecided.
P/E21.2
Market value$569.1M
1 year+111%
5 years+82%
Charts
As reported to the SEC, without any scoring.
Puma Biotechnology, Inc. (PBYI) reported revenue of $57M in Q2 2026 (quarter ended Jun 30, 2026), up 7.8% from the same quarter a year earlier. That came with a gross margin of 78% and net income of $8.2M (14% of revenue). For the full year FY2025, revenue was $228M (−0.9% year on year) and net income $31M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.